Desoxypipradrol Stats & Data

2‑DPMP is a very long‑acting, highly potent NDRI; delayed onset (up to ~2 h) often leads to premature redosing and multi‑day wakefulness. Volumetric dosing and a 0.001 g (milligram) scale reduce overdose risk. Re‑dosing during the same day (or within 24 h) significantly increases chances of severe agitation, paranoia, and insomnia lasting 1–3 days, with numerous reports of psychosis after multi‑day wakefulness. Intranasal use is commonly reported as caustic to nasal mucosa and provides no safety benefit over oral dosing. Because of the long half‑life, avoid evening dosing; plan for sleep disruption and do not ‘stack’ doses if effects feel light in the first 2 hours. People with cardiovascular disease, hypertension, arrhythmia, or significant anxiety/psychotic disorders should avoid 2‑DPMP due to elevated risks (tachycardia, hypertension, panic, psychosis). If severe symptoms appear (chest pain, confusion, hyperthermia, seizures, or unmanageable agitation), seek urgent medical care; supportive cooling, hydration, and clinical benzodiazepines are typical first‑line approaches for stimulant toxicity—do not rely on alcohol or self‑sedation. Mislabeling/substitution has historically been an issue (e.g., ‘Ivory Wave’ products); use professional drug checking where available and wait at least 2 hours after an initial test dose before any consideration of re‑dose. Repeated day‑to‑day use rapidly increases adverse mental effects and yields diminishing functional benefits; spacing uses by multiple weeks lowers harm. Avoid driving or high‑risk tasks with sleep loss or residual stimulation present.